Viking Therapeutics said trial participants on its GLP-1/GIP obesity candidate VK-2735 maintained weight loss after stepping down from weekly dosing to every-other-week or monthly schedules, according to the company’s update. Analysts cited as supportive evidence that less frequent administration could strengthen competitive positioning. Separately, market attention on GLP-1/GIP and next-generation incretin strategies remains intense as companies explore expanded use beyond weight loss, including cardiometabolic and neuropsychiatric indications. Together, these data points reinforce the commercial priority of dosing convenience and long-term maintenance in obesity therapeutics, where payer coverage and adherence will influence real-world outcomes.